Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents.
No abstract is available for this record.
Bibliographic context
- Journal
- Unknown
- Date
- 2023-06-30
- Source
- Europe PMC
- PubMed
- 37581427
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.Human Brain Mapping · 2026-06-30Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depressionPharmacological Research · 2026-06-10Studies on enzymatic hydrolysis of psilocin- O -glucuronide for screening of psilocin in human urine by liquid chromatography-triple quadrupole tandem mass spectrometryJournal of Analytical Toxicology · 2026-05-26The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising ApproachDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21Effects of Psilocybin on Attentional Set-Shifting Following Chronic Unpredictable Stress in Rats (Abstract ID: 231339)Journal of Pharmacology and Experimental Therapeutics · 2026-04-30Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.International Journal of Eating Disorders · 2026-07-01